Products for Research Use Only
RegisterLogin

Oroxin B

CAT: 0804-HY-N1435-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N1435-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT[1]. Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells[2].
CAS Number
114482-86-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; PI3K; PTEN
Type
Natural Products
Related Pathways
Apoptosis; Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/oroxin-b.html
Purity
99.39
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C1C=C(C2=CC=CC=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O)O)O4)O)O)O)=C(O)C(O)=C13
Molecular Formula
C27H30O15
Molecular Weight
594.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Li NN, et al. Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer. Pharmacogn Mag. 2018 Apr-Jun;14 (54) :207-213.|[2]Yang P, et al. Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy. Toxicol Appl Pharmacol. 2015 Oct 15;288 (2) :269-79.|[3]Lu R, et al. Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy. Front Endocrinol (Lausanne) . 2022 Dec 1;13:1060721.|[4]Huang Y, et al. Oroxin B improves metabolic-associated fatty liver disease by alleviating gut microbiota dysbiosis in a high-fat diet-induced rat model. Eur J Pharmacol. 2023 Jul 15;951:175788.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N2025-01Oroxin A
HY-N2025ROroxin A (Standard)
HY-W777997Nocardicin B
HY-W713570-01Nectandrin B
HY-W777995-01Clindamycin B
HY-W013935-01Bisphenol B
HY-N8507Tunicamycin B
HY-N7046-01Silybin B
HY-162836-01Rifamycin B
HY-N7637-01Tubuloside B

Alternative Products

CatalogName
N2238-20Oroxin A
N2237-20Oroxin B
371774Oroxin A discontinued

Popular Products